Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial.
Publication Title
American journal of hematology
Document Type
Article
Publication Date
8-21-2018
Abstract
Ibrutinib demonstrated superior response rates and survival for treatment-naïve chronic lymphocytic leukemia (CLL) patients in a pivotal study that excluded patients younger than 65 (
Area of Special Interest
Cancer
Specialty/Research Institute
Oncology
Specialty/Research Institute
Hematology
COinS
